Linfoma burkitt-like em um lactente: relato de caso

Os linfomas não Hodgkin da infância, incluindo os linfomas de Burkitt e Burkitt-like são raros em lactentes. Um caso de linfoma não Hodgkin B em uma lactente de 13 meses de idade é descrito. Ao diagnóstico a paciente apresentava extenso comprometimento abdominal associado à ascite, derrame pleural e síndrome de lise tumoral. A análise imunofenotípica mostrou um fenótipo compatível com células linfóides oriundas do centro germinativo e a origem clonal dessas células foi demonstrada por reação em cadeia da polimerase. Não foi demonstrada associação do linfoma com infecção pelo vírus Epstein-Barr e/ou virus da imunodeficiência adquirida. O caso apresentado enfatiza a necessidade de considerar o diagnóstico de linfoma mesmo em lactentes.Childhood non-Hodgkin's lymphomas, including Burkitt and Burkitt-like, are rarely diagnosed in infants. A case of B-cell lymphoma in a 13-month-old girl with extensive abdominal disease, ascites, pleural effusion, and tumor lysis syndrome is reported. Phenotypic analysis showed a germinal center B-cell phenotype, and a B-cell clonality was confirmed by polymerase chain reaction. There was no evidence of Epstein-Barr and HIV infection. The case herein reported emphasizes the need for considering the diagnosis of lymphoma even in very young children

Influencia del vermicompost y sus lixiviados sobre la germinación de hortalizas en un suelo sódico

The objective of this work was to evaluate the influence of vermicompost and leakage on seed germination and growth of vegetable seedlings in sodium soil. The study was carried out in vegetable species: lettuce, cabbage and tomato, in total three tests were established to analyze the individual behavior of each vegetable subjected to four treatments with three repetitions. The evaluated treatments were T1 (Sodium soil. Control); T2 (Sodium soil + Vermicompost); T3 (Sodium Soil + Vermicompost Leakage); T4 (Sodium soil + Vermicompost + Vermicompost leakage). In three vegetables evaluated, treatments T2 and T4 were those that stood out with germination index values ​​that were between 112 and 172%. This trend of better response of vegetables towards T2 and T4 was maintained in the variables of total seedling weight, hypocotyl and radicle length. In this way we can conclude that, by applying vermicompost and its leakage it is possible to improve the biological response of vegetables grown in sodium soils. Vermicompost has a high MO content (43.6%), this could explain the positive response of the treatment containing this product T2. As well as the remarkable synergy of both by-products in T4. However, further studies are needed to understand in greater detail the mechanisms with which these organic compounds reduce the antagonistic effects of sodium on plant physiology.El objetivo del presente trabajo fue evaluar la influencia del vermicompost y sus lixiviados sobre la germinación de semillas y desarrollo de plántulas de hortalizas en un suelo sódico. El estudio se efectuó en especies de hortalizas: lechuga, col y tomate, en total se establecieron tres ensayos para analizar el comportamiento individual de cada hortaliza sometida a cuatro tratamientos con tres repeticiones. Los tratamientos evaluados fueron T1 (Suelo sódico. Control); T2 (Suelo sódico + Vermicompost); T3 (Suelo sódico + Lixiviado de Vermicompost); T4 (Suelo sódico + Vermicompost + Lixiviado de Vermicompost). En las tres hortalizas evaluadas los tratamientos T2 y T4 fueron los que sobresalieron con valores de índice de germinación que se ubicaron entre 112 y 172%. Esta tendencia de mejor respuesta de las hortalizas hacia los T2 y T4 se mantuvo en las variables de peso total de plántulas, longitud del hipocotilo y de la radícula. De este modo podemos concluir que, mediante la aplicación de vermicompost y sus lixiviados es posible mejorar la respuesta biológica de hortalizas cultivadas en suelos sódicos. El vermicompost posee alto contenido de MO (43.6%), esto podría explicar la respuesta positiva del tratamiento que contiene este subproducto T2. Así como la notable sinergia de ambos subproductos en el T4. Sin embargo, aún hace falta profundizar en estudios orientados a entender con mayor detalle los mecanismos con los que estos compuestos orgánicos reducen los efectos antagónicos del sodio sobre la fisiología vegetal

Clonal chromosomal mosaicism and loss of chromosome Y in elderly men increase vulnerability for SARS-CoV-2

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) had an estimated overall case fatality ratio of 1.38% (pre-vaccination), being 53% higher in males and increasing exponentially with age. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, we found 133 cases (1.42%) with detectable clonal mosaicism for chromosome alterations (mCA) and 226 males (5.08%) with acquired loss of chromosome Y (LOY). Individuals with clonal mosaic events (mCA and/or LOY) showed a 54% increase in the risk of COVID-19 lethality. LOY is associated with transcriptomic biomarkers of immune dysfunction, pro-coagulation activity and cardiovascular risk. Interferon-induced genes involved in the initial immune response to SARS-CoV-2 are also down-regulated in LOY. Thus, mCA and LOY underlie at least part of the sex-biased severity and mortality of COVID-19 in aging patients. Given its potential therapeutic and prognostic relevance, evaluation of clonal mosaicism should be implemented as biomarker of COVID-19 severity in elderly people. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, individuals with clonal mosaic events (clonal mosaicism for chromosome alterations and/or loss of chromosome Y) showed an increased risk of COVID-19 lethality

La salud y la seguridad ocupacional en el laboratorio clínico de urgencias del Hospital CAM

Describe y evalua los riesgos físicos, químicos y biológicos, ergonómicos, psicosociales y valoración de los índices ambientales y biológicos. Prioriza los principales riesgos existentes; Justifica la necesidad de implementar un programa de Gestión en Seguridad y Salud Ocupacional. Se elabora un perfil de los riesgos en laboratorio clínico, con la intención de que sirva de guía para futuros estudios. Se observa algunas normasDiplomado en Seguridad y Salud LaboralCuenc

Influencia del vermicompost y sus lixiviados sobre la germinación de hortalizas en un suelo sódico

The objective of this work was to evaluate the influence of vermicompost and leakageon seed germination and growthof vegetable seedlings in sodium soil. The study was carried out in vegetable species: lettuce, cabbage and tomato, in total three tests were established to analyze the individual behavior of each vegetable subjected to four treatments with three repetitions. The evaluated treatments were T1 (Sodium soil. Control); T2 (Sodium soil + Vermicompost); T3 (Sodium Soil + Vermicompost Leakage); T4 (Sodium soil + Vermicompost + Vermicompost leakage). In three vegetables evaluated, treatments T2 and T4 were those that stood out with germination index values that were between 112 and 172%. This trend of better response of vegetables towards T2 and T4 was maintained in the variables of total seedling weight, hypocotyl and radicle length. In this way we can conclude that,by applying vermicompost and its leakageit is possible to improve the biological response of vegetables grown in sodium soils. Vermicompost has a high MOcontent (43.6%), this could explain the positive response of the treatment containing this product T2. As well as the remarkable synergy of both by-products in T4. However, further studies are needed to understand in greater detail the mechanisms with which these organic compounds reduce the antagonistic effects of sodium on plant physiology.El objetivo del presente trabajo fue evaluar la influencia del vermicompost y sus lixiviados sobre la germinación de semillas y desarrollo de plántulas de hortalizas en un suelo sódico. El estudio se efectuó en especies de hortalizas: lechuga, col y tomate, en total se establecieron tres ensayos para analizar el comportamiento individual de cada hortaliza sometida a cuatro tratamientos con tres repeticiones. Los tratamientos evaluados fueron T1 (Suelo sódico. Control); T2 (Suelo sódico + Vermicompost); T3 (Suelo sódico + Lixiviado de Vermicompost); T4 (Suelo sódico + Vermicompost + Lixiviado de Vermicompost). En las tres hortalizas evaluadas los tratamientos T2 y T4 fueron los que sobresalieron con valores de índice de germinación que se ubicaron entre 112 y 172%. Esta tendencia de mejor respuesta de las hortalizas hacia los T2 y T4 se mantuvo en las variables de peso total de plántulas, longitud del hipocotilo y de la radícula. De este modo podemos concluir que, mediante la aplicación de vermicompost y sus lixiviados es posible mejorar la respuesta biológica de hortalizas cultivadas en suelos sódicos. El vermicompost posee alto contenido de MO (43.6%), esto podría explicar la respuesta positiva del tratamiento que contiene este subproducto T2. Así como la notable sinergia de ambos subproductos en el T4. Sin embargo, aún hace falta profundizar en estudios orientados a entender con mayor detalle los mecanismos con los que estos compuestos orgánicos reducen los efectos antagónicos del sodio sobre la fisiología vegetal

Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial

Background: Additional safe and efficacious vaccines are needed to control the COVID-19 pandemic. We aimed to analyse the efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate. Methods: HERALD is a randomised, observer-blinded, placebo-controlled, phase 2b/3 clinical trial conducted in 47 centres in ten countries in Europe and Latin America. By use of an interactive web response system and stratification by country and age group (18–60 years and ≥61 years), adults with no history of virologically confirmed COVID-19 were randomly assigned (1:1) to receive intramuscularly either two 0·6 mL doses of CVnCoV containing 12 μg of mRNA or two 0·6 mL doses of 0·9% NaCl (placebo) on days 1 and 29. The primary efficacy endpoint was the occurrence of a first episode of virologically confirmed symptomatic COVID-19 of any severity and caused by any strain from 15 days after the second dose. For the primary endpoint, the trial was considered successful if the lower limit of the CI was greater than 30%. Key secondary endpoints were the occurrence of a first episode of virologically confirmed moderate-to-severe COVID-19, severe COVID-19, and COVID-19 of any severity by age group. Primary safety outcomes were solicited local and systemic adverse events within 7 days after each dose and unsolicited adverse events within 28 days after each dose in phase 2b participants, and serious adverse events and adverse events of special interest up to 1 year after the second dose in phase 2b and phase 3 participants. Here, we report data up to June 18, 2021. The study is registered at ClinicalTrials.gov, NCT04652102, and EudraCT, 2020–003998–22, and is ongoing. Findings: Between Dec 11, 2020, and April 12, 2021, 39 680 participants were enrolled and randomly assigned to receive either CVnCoV (n=19 846) or placebo (n=19 834), of whom 19 783 received at least one dose of CVnCoV and 19 746 received at least one dose of placebo. After a mean observation period of 48·2 days (SE 0·2), 83 cases of COVID-19 occurred in the CVnCoV group (n=12 851) in 1735·29 person-years and 145 cases occurred in the placebo group (n=12 211) in 1569·87 person-years, resulting in an overall vaccine efficacy against symptomatic COVID-19 of 48·2% (95·826% CI 31·0–61·4; p=0·016). Vaccine efficacy against moderate-to-severe COVID-19 was 70·7% (95% CI 42·5–86·1; CVnCoV 12 cases in 1735·29 person-years, placebo 37 cases in 1569·87 person-years). In participants aged 18–60 years, vaccine efficacy against symptomatic disease was 52·5% (95% CI 36·2–64·8; CVnCoV 71 cases in 1591·47 person-years, placebo, 136 cases in 1449·23 person-years). Too few cases occurred in participants aged 61 years or older (CVnCoV 12, placebo nine) to allow meaningful assessment of vaccine efficacy. Solicited adverse events, which were mostly systemic, were more common in CVnCoV recipients (1933 [96·5%] of 2003) than in placebo recipients (1344 [67·9%] of 1978), with 542 (27·1%) CVnCoV recipients and 61 (3·1%) placebo recipients reporting grade 3 solicited adverse events. The most frequently reported local reaction after any dose in the CVnCoV group was injection-site pain (1678 [83·6%] of 2007), with 22 grade 3 reactions, and the most frequently reported systematic reactions were fatigue (1603 [80·0%] of 2003) and headache (1541 [76·9%] of 2003). 82 (0·4%) of 19 783 CVnCoV recipients reported 100 serious adverse events and 66 (0·3%) of 19 746 placebo recipients reported 76 serious adverse events. Eight serious adverse events in five CVnCoV recipients and two serious adverse events in two placebo recipients were considered vaccination-related. None of the fatal serious adverse events reported (eight in the CVnCoV group and six in the placebo group) were considered to be related to study vaccination. Adverse events of special interest were reported for 38 (0·2%) participants in the CVnCoV group and 31 (0·2%) participants in the placebo group. These events were considered to be related to the trial vaccine for 14 (<0·1%) participants in the CVnCoV group and for five (<0·1%) participants in the placebo group. Interpretation: CVnCoV was efficacious in the prevention of COVID-19 of any severity and had an acceptable safety profile. Taking into account the changing environment, including the emergence of SARS-CoV-2 variants, and timelines for further development, the decision has been made to cease activities on the CVnCoV candidate and to focus efforts on the development of next-generation vaccine candidates. Funding: German Federal Ministry of Education and Research and CureVac